Neurology · PTSDTrial Updateclinicalmid-term

Phase 2 Trial of Daridorexant for PTSD Under Adaptive Platform Design

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/1/2026, 12:32:18 PM

Assessment confidence: 60% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing Phase 2 trial of daridorexant for PTSD represents a significant opportunity for Idorsia Pharmaceuticals to strengthen its portfolio in a competitive therapeutic area. Positive trial outcomes could lead to enhanced market positioning and potential revenue growth in the PTSD treatment landscape. Regulatory context from FDA (Office of New Drugs Custom Medical Queries (OCMQs) for Safety Signal Detection in Clinical Trial Data - 06/23/2026) supports the near-term read. Assessment grounded in 19 ranked evidence items (7 high-relevance).

Strategic Assessment

Success in this trial could enhance Idorsia Pharmaceuticals' portfolio and market position in PTSD treatment. The strongest clinical anchor is Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant (ClinicalTrials.gov), entity match (idorsia pharmaceuticals). In Neurology · PTSD, 3 regulatory and 5 competitive items passed relevance filtering for Idorsia Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform. This trial positions daridorexant as a potential treatment option in a competitive landscape for PTSD therapies.

Regulatory Outlook

Regulatory risk is concentrated around Office of New Drugs Custom Medical Queries (OCMQs) for Safety Signal Detection in Clinical Trial Data - 06/23/2026 (FDA). Moderate corpus alignment. The trial's results will be critical for future regulatory submissions and could influence the approval process for daridorexant as a treatment for PTSD.

Key Risks

Elevated medium regulatory exposure for Idorsia Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, daridorexant could capture market share in the PTSD treatment sector, impacting revenue streams for Idorsia Pharmaceuticals and potentially altering competitive dynamics.
Upside for Idorsia Pharmaceuticals may improve if Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform (Roche) delivers favorable follow-through.
Upside for Idorsia Pharmaceuticals may improve if Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Success in this trial could enhance Idorsia Pharmaceuticals' portfolio and market position in PTSD treatment.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any announcements regarding the adaptive platform's outcomes.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Office of New Drugs Custom Medical Queries (OCMQs) for Safety Signal Detection in Clinical Trial Data - 06/23/2026
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
ClinicalTrials.gov: Essentials for Academic Medical Centers - 07/14/2026
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant
ClinicalTrials.govhigh relevance
Entity match (idorsia pharmaceuticals)
FDA document
View source
Phase II: Engagement and Clinical Impact of the Teleo Virtual Therapy Platform in Clinical Settings
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effect of Animation Video and Training Booklet Designed on Breast Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Non-Inferiority Trial of TrIGR for PTSD
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Trial to Optimize Just-in-Time Adaptive Intervention for Binge Eating & Weight-related Behaviors
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Phase 3 Trial of Navenibart for Hereditary Angioedema Initiated by Astria Therapeutics
Humanexa Signalsmedium relevance
Moderate corpus alignment
Phase I/II Trial of Lentiviral Gene Transfer for XSCID in Children Over Two Years
Humanexa Signalsmedium relevance
Moderate corpus alignment

Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Targeted proteoform degradation for precision drug design, delivery, and therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Idorsia Pharmaceuticals

Commercial impact

medium

If successful, daridorexant could capture market share in the PTSD treatment sector, impacting revenue streams for Idorsia Pharmaceuticals and potentially altering competitive dynamics.

Regulatory impact

medium

The trial's results will be critical for future regulatory submissions and could influence the approval process for daridorexant as a treatment for PTSD.

What to watch

Monitor trial results and any announcements regarding the adaptive platform's outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.